PADMA-28, a Tibetan herbal preparation is an inhibitor of inflammatory cytokine production

European Cytokine Network

Volumn 15, Issue 3, 2004, Pages 203-209

  Barak, Vivian ^a,b   Kalickman, Inna ^a   Halperin, Tal ^a   Birkenfeld, Shlomo ^a   Ginsburg, Isaac ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b Israeli Cytokine Standard Lab   (Israel)

Author keywords

Herbal medicine; Inflammatory cytokines; PADMA 28

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; CYTOKINE; ENDOTOXIN; HERBACEOUS AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOTEICHOIC ACID; PADMA 28; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHINA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; HERBAL MEDICINE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNE SYSTEM; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; INTERMITTENT CLAUDICATION; LOW DRUG DOSE; MONOCYTE; SALMONELLA TYPHI; STREPTOCOCCUS GROUP A; TRADITIONAL MEDICINE;

CYTOKINES; DRUGS, CHINESE HERBAL; HUMANS; MONOCYTES; PLANT EXTRACTS;

BACTERIA (MICROORGANISMS); NELUMBO NUCIFERA; SALMONELLA; SALMONELLA TYPHI; STREPTOCOCCUS; STREPTOCOCCUS SP. 'GROUP A';

EID: 6344284117     PISSN: 11485493     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. British Herbal Pharmacopœia. British Herbal Medicine Association. 1998. West Yorks, p 186.
2. Matzner Y, Sallon S. 1995. The effect of PADMA 28, a traditional Tibetan herbal preparation, on human neutrophil function. J Clin Lab Immun. 46: 13.
3. Suter M, Richter C. 2000. Anti- and pro- oxidative properties of PADMA 28, a Tibetan herbal formulation. Redox Report. 5: 17.
4. Stampfli S, Schwabli B. 2001. The antioxidative and anti-inflammatory properties of PADMA 28. Schweiz Zschr Ganzheits Medizin. 13: 242.
5. Moeslinger T, Friedl R, Volt I, Brunner M, Koller E, Spieckermann PG. 2000. Inhibition of inducible nitric oxide synthesis by the herbal preparation PADMA 28 in macrophage cell line. Can J Physiol Pharmacol. 78: 861.
6. Ginsburg I, Sadovnik M, Sallon, S et al. 1999.PADMA 28, a traditional Tibetan herbal preparation inhibits the respiratory burst in human neutrophils, the killing of epithelial cells by mixtures of oxidants and pro-inflammatory agonists and peroxidation of lipids. Inflammopharmacology. 7: 47.
7. Weseler A, Saller R, Reichling J. 2002. Comparative investigation of the animicrobial activity of PADMA 28 and selected european herbal drugs. Forsch Komplementarmed Klass Naturheilkd. 9: 346.
8. Winther K, Kharazmi A, Himmelstrup H, Drabaek H, Mehelsen J. 1994. PADMA 28, a botanical compound, decreases the oxidative burst response of monocytes and improves fibrinolysis in patients with stable intermittent claudication. Fibrinolysis. 8: 47.
9. Schraeder R, Nachbur B, Mahker F. 1985. [Effects of the Tibetan Herbal preparation PADMA 28 in intermittent claudication] Die wirkung des tibetanischen Krauterpraparates PADMA 28 auf die Claudicatio intemittens. Schwiez Med Wochenschr. 115: 752.
10. Samochowiec L, Wojcicki J, Kosmider K, Dadej R, Smulski H. 1987. Wirksamkeitsprufung von PADMA 28 bei der Behandlung von patienten mit chronischen arteriellen durchblutungsstorungen. Herba Polonica. 33: 29.
11. Drabaek H, Mehlsen J, Himmelstrup H, Wnther K. 1993. A botanical compound, PADMA 28, increases walking distance in stable intermittent claudiation. Angiology. 44: 863.
12. Smulski HS, Wojcicki J. 1995. Placebo controlled, double blind trial to determine the efficacy if the tibetan plant preparation PADMA 28 for intermittent claudiation. Alternative Therapies. 33: 4.
13. Wojcicki J, Samochowiec L. 1996. Controlled double-blind study of PADMA 28 in Angina Pectoris. Herba Polonica XXXII. 107.
14. Sallon S, Beer G, Rosenfeld J, et al. 1998. The efficacy of PADMA 28, a herbal preparation, in the treatment of intermittent claudication: a double-blind pilot study with objective assessment of chronic occlusive arterial disease patients. J Vascular Investigation. 4: 129.
15. Samochowiec J, Palacz A, Bobnis W, Lisiecka B. 1992. Oscillating potentials of the electroretinogram in the evaluation of the effects of PADMA 28 on lipid metabolism and vascular changes in humans. Phototherapy Research. 6: 200.
16. Dinarello CA. 1996. Biologic basis for Interleukin - 1 in disease. Blood. 87: 2095.
17. Barak V, Schwartz A, Kalickman I, Nisman B, Gurman G, Shoenfeld Y. 1998. Hypophosphatemia as a diagnostic tool in sepsis: the role of cytokines. Am J Med. 104: 40.
18. Nagler A, Bishara A, Brautbar C, Barak V. 1998. Dysregulation of inflammatory cytokines in unrelated bone marrow transplantation. Cytokine Cell Mol Ther. 4: 161.
19. Barak V, Nisman B, Polliack A, Vannier E, Dinarello CA. 1998. Circulating levels of IL-1 family members in Hairy Cell Leukemia. Correlation with disease activity and response to treatment. Eur Cytokine Netw/|roman|. 9: 33.
20. Barak V. 1995. Cytokine receptors in disease. Isr J Med Sci. 31: 1.
21. Opal SM, Cohen J. 1999. Clinical Gram positive bacterial sepsis: does it amentally differ from Gram negative bacterial sepsis? Crit Care Med. 27: 1608.
22. Ginsburg I. 2002. Role of lippoteichoic acid in infection and inflammation. Lancet Infect Dis. 2: 171.
23. Dishon T, Finkel R, Marcus Z, Ginsburg I. 1967. Cell-sensitizing products of streptococci. Immunology. 13: 555.
24. Barak V, Fuks Z, Gallili N, Treves AJ. 1983. Selection and continuous growth of antigen specific human T cell lines by antigen treated monocytes. Ear J Immunol 13: 952.
25. Barak V, Halperin T, Kalichman I. 2001. The effect of Sambucol black elderberry, a natural product based on the production of human cytokines: 1. Inflammatory cytokines. Eur Cytokine Netw. 12: 290.
26. Barak V, Halperin T, Birkenfeld S, Kalickman I. 2002. The effects of Herbal remedies on the production of human inflammatory cytokines and anti-inflammatory cytokines. Isr Med Assoc J. 4: 919.
27. Ginsburg I. 2002. The role of bacteriolysis in the pathophysiology of inflammation, infection and post-infectious sequelae. APMIS. 110: 753.
28. Ginsburg I. 1999. Multidrug strategies are necessary to inhibit the synergistic mechanisms causing tissue damage and organ failure in post infectious sequelae. Inflammopharmacology. 7: 47.
29. Janssens S, Beyaert R. 2003. Role of Toll-like receptors in pathogen recognition. Clin Microbiol Rev. 16: 637.
30. Gladysz A, Juszczyk I, Brzosko WJ. 1993. Influence of PADMA 28 on patients with chronic active hepatitis type B. Phytotherapy Research. 7: 244.
31. Weiss L, Barak V, Zeira M et al. 2002. Cytokine production in Linomide-treated NOD mice and the potential role of Th1/Th 2 shift on autoimmune and anti inflammatory processes. Cytokine. 19: 85.
32. Melchart D, Linde K, Worku F, Sarkady L, Holzmann M, Jurcic K, Wagner H. 1995. Results of five randomized studies on the immunomodulatory activity of preparations of Echinacea. J Altern Complement Med. 1: 145.
33. Burger RA, Torres AR, Warren RP, Caldwell VD, Hughes BG. 1997. Echinacea- induced cytokine production by human macrophages. Int J Immunopharmacol. 19: 371.
34. Zakay-Rones Z, Varsano N, Zlotnik M, Manor O, Regev L, Schlesinger M, Mamcuoglu M. 1995. Inhibition of several strains of influenza virus in vitro and reduction of symptoms by an elder-berry extract (Sambucus nigra L.) during an outbreak of Influenza B Panama. J Altern Compl Med. 1: 361.
35. Ginsburg I, Cohen R. 1995. Cell damage in inflammatory and infectious sites might involve a coordinated cross - talk among oxidants, microbial hemolysins and amphiphiles, cationic proteins, phospholipases, fatty acids and proteinases. Free Rad Res. 22: 489.
36. Ginsburg I, Ward PA, Varani J. 1999. Can we learn from the pathogenetic strategies of group A hemolytic streptococci how tissues are destroyed and organs fail in postinfectious and inflammatory sequeale? FEMS Immunol Med Microbiol. 25: 325.